Susquehanna International Group
RUBY

Susquehanna International Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Susquehanna International Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,800
Closed -$170K – 14401
2022
Q1 		$170K Buy
30,800
+700
+2% +$4.45K ﹤0.01% 11436
2021
Q4 		$291K Buy
+30,100
New +$417K ﹤0.01% 10574
2021
Q3 		– Sell
-28,900
Closed -$705K – 13876
2021
Q2 		$705K Sell
28,900
-173,900
-86% -$4.35M ﹤0.01% 8728
2021
Q1 		$5.37M Buy
202,800
+153,400
+311% +$2.24M ﹤0.01% 3777
2020
Q4 		$375K Buy
+49,400
New +$293K ﹤0.01% 8852

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's RUBY Position: Q4 2022 in Review

Susquehanna International Group sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 96,985 shares — an estimated $42K sold.

Susquehanna International Group first reported a position in RUBY in Q2 2019 and held it in 11 quarters. The position peaked at $860K in Q4 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Susquehanna International Group reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Susquehanna International Group sold 96,985 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $42K.
  • Susquehanna International Group first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 11 quarters.
  • Susquehanna International Group's Rubius Therapeutics, Inc position peaked at $860K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.